Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation (IMRX) is a clinical-stage biopharmaceutical company leveraging computational biology to advance oncology and neurology therapeutics. This news hub provides investors and researchers with essential updates on the company's scientific progress, strategic partnerships, and regulatory developments.
Access real-time announcements about clinical trial milestones, research collaborations, and platform innovations. Our curated collection includes earnings reports, regulatory filings, and analyses of the company's proprietary Disease Cancelling Technology platform. Stay informed about developments in key therapeutic areas including cancer neuroscience and precision oncology targets.
Key updates cover partnership expansions with pharmaceutical leaders, preclinical data publications, and progress toward IND submissions. The resource serves both technical experts seeking molecular mechanism insights and investors monitoring pipeline progression. Content is rigorously verified to ensure accuracy across scientific and financial disclosures.
Bookmark this page for streamlined access to Immuneering's latest advancements in translational bioinformatics and therapeutic candidate development. Regularly updated to reflect new developments in computational drug discovery and clinical-stage research programs.
Immuneering (NASDAQ:IMRX) reported Q2 2025 financial results and significant clinical progress for its lead drug atebimetinib. The company highlighted exceptional 94% overall survival at 6 months in first-line pancreatic cancer patients (N=34) treated with atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP), compared to 67% with standard care.
Key developments include a newly granted U.S. composition of matter patent extending exclusivity into 2042, and a notable case of a third-line pancreatic cancer patient maintaining partial response for over 18 months on atebimetinib monotherapy. The company reported Q2 2025 net loss of $14.4 million ($0.40 per share) and cash position of $26.4 million, with runway into 2026.
Immuneering plans to share updated survival data in Q3 2025 and has submitted an End of Phase 2 meeting request to FDA, with pivotal trial initiation expected in 2026.
Immuneering (Nasdaq: IMRX) has secured a crucial U.S. composition of matter patent for atebimetinib, its innovative cancer drug candidate. The patent, expected to provide exclusivity until August 2042, covers this first-in-class deep cyclic MEK inhibitor designed as a once-daily pill to combat cancer drug resistance.
Clinical data has shown remarkable results, with 94% probability of 6-month survival in first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy, compared to 67% with standard care. The drug has received FDA Fast Track designations for first- and second-line pancreatic cancer treatment and NRAS-mutant melanoma, along with orphan drug designation for pancreatic cancer.
Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company, announced its participation in the upcoming Jefferies Global Healthcare Conference. The event will take place at the Marriott Marquis in New York City from June 4-5, 2025.
The company's management team, including CEO Ben Zeskind, CMO Igor Matushansky, CSO Brett Hall, CBO Harold Brakewood, and CAO Mallory Morales, will deliver a company presentation on June 5 from 8:45-9:15 am ET. The presentation will focus on Immuneering's pipeline, platform, and business strategy. The event will also include one-on-one investor meetings.
A live webcast of the presentation will be available and later archived in the Investor Relations section of Immuneering's website.
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference scheduled for April 7-10, 2025. The company's management team will deliver a presentation on April 9, 2025, from 1:30 - 2:10 pm ET.
The presentation will feature key executives including CEO Ben Zeskind, CSO Brett Hall, CMO Igor Matushansky, CBO Harold Brakewood, CLO Michael Bookman, and CAO Mallory Morales. They will discuss Immuneering's pipeline, platform, and business strategy. The event will include both a company presentation and one-on-one investor meetings.
Interested parties can access the live webcast and archived recording through the Investor Relations section of Immuneering's website under Events & Presentations.
Immuneering (Nasdaq: IMRX) has granted an inducement stock option award to its newly appointed Chief Medical Officer, Dr. Igor Matushansky. The award, issued on March 21, 2025, consists of options to purchase 118,000 shares of Class A common stock at an exercise price of $1.80 per share, matching the closing price on Nasdaq Global Market that day.
The stock option, granted under the company's 2025 Employment Inducement Award Plan and approved by the Board of Directors, has a ten-year term. The vesting schedule includes 25% vesting on March 17, 2026, with the remaining 75% vesting in monthly installments over the following three years, achieving full vesting by March 17, 2029. The grant was made under Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Immuneering (NASDAQ: IMRX) has reported promising results from its Phase 2a trial of IMM-1-104 in pancreatic cancer combinations. The drug showed a 43% objective response rate (ORR) when combined with modified gemcitabine/nab-paclitaxel and 50% ORR with modified FOLFIRINOX, significantly exceeding historical benchmarks of 23% and 32% respectively.
The company highlighted a notable case study of a Phase 1 pancreatic cancer patient maintaining stable disease for over 13 months on IMM-1-104 monotherapy, with a 91% reduction in CA 19-9 levels. Immuneering secured a clinical trial agreement with Regeneron to evaluate IMM-1-104 with Libtayo in non-small cell lung cancer.
Financial results show cash position of $36.1 million as of December 31, 2024, with an additional $13.7 million raised in January 2025. The company reported a net loss of $61.0 million for full year 2024. Cash runway is expected to extend into 2026.
Immuneering (IMRX) has appointed Dr. Igor Matushansky as Chief Medical Officer to lead their clinical activities. Dr. Matushansky will oversee the ongoing Phase 2a study of IMM-1-104 in pancreatic cancer, lung cancer, and melanoma, as well as plans for a pivotal Phase 3 trial in pancreatic cancer.
The company plans to present updated data from the Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025. Earlier Phase 2a data from January showed promising results for first-line pancreatic cancer patients, suggesting improved efficacy and tolerability compared to standard care.
Dr. Matushansky brings extensive oncology experience from previous roles at Sail Biomedicines, Ipsen Pharmaceuticals, Hookipa Pharma, and Daiichi Sankyo. At Ipsen, he oversaw the NAPOLI-3 trial that led to NALIRIFOX's approval for first-line pancreatic cancer treatment.
FAQ
What is the current stock price of Immuneering (IMRX)?
What is the market cap of Immuneering (IMRX)?
